CRC Clinical Trial - Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to compare whether a 3-month treatment is at least not inferior to a 6-month treatment (FOLFOX-4 6 vs. 12 cycles or XELOX 4 cycles vs. 8 cycles) in terms of RFS in patients with high risk stage II or stage III radically resected colon cancer.

Clinical Trial Description

Six months of adjuvant chemotherapy with 5-FU and oxaliplatin for patients with stage III colon cancer is the world-wide standard of care, based on the MOSAIC and C-07 trials. However, it leads to significant cost, toxicity, and inconvenience. In particular, the onset of oxaliplatin induced cumulative dose-dependent neuropathies is a significant issue. The ability to maintain efficacy with a reduced duration of therapy would have clear advantage to patients, to providers, and to the health care system.

Multiple large trials in the 1990s demonstrated that the previous standard of 12 months of therapy could be reduced to 6 months. A single small trial with 5-FU alone demonstrated similar outcomes for 3 versus 6 months of therapy. Thus, it is proposed to definitively evaluate the non-inferiority of 3 months of oxaliplatin-based adjuvant chemotherapy versus the current standard of 6 months. The primary endpoint will be disease-free survival (DFS).

It is essential to have sufficient power to eliminate the possibility of clinically meaningful inferiority of 3 months of therapy: a huge number of patients will be necessary. Previous efforts and experience have conclusively demonstrated that in colon cancer, a single, global trial is impractical. Consequently, an international, prospective pooled analysis will be performed, gathering data of independent trials run in different countries, to answer the single primary hypothesis that 3 months of adjuvant therapy with FOLFOX/XELOX is non-inferior to the current standard of 6 months. Among six planned countries, the Greek intergroup will conduct one of these trials. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01308086
Study type	Interventional
Source	Hellenic Oncology Research Group
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	October 2010
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05002270` - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation	Phase 1/Phase 2
Recruiting	`NCT04557449` - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04981119` - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Active, not recruiting	`NCT04585035` - Study to Evaluate D-1553 in Subjects With Solid Tumors	Phase 1/Phase 2
Completed	`NCT03665285` - A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03336658` - Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer
Recruiting	`NCT06445062` - Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03875313` - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05382377` - NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors	Early Phase 1
Active, not recruiting	`NCT05314309` - Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening
Recruiting	`NCT06259552` - A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors	Phase 1
Completed	`NCT05976282` - Addressing Colorectal Cancer in South Florida Firefighters	N/A
Recruiting	`NCT01593098` - A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)
Recruiting	`NCT03597581` - A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer	Phase 1
Terminated	`NCT05368688` - Microbiome in Colorectal Cancer Onset and Progression
Completed	`NCT03965845` - A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT06455254` - Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM	Phase 2
Not yet recruiting	`NCT03601598` - A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC	Phase 1/Phase 2
Completed	`NCT02161549` - Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy	N/A
Active, not recruiting	`NCT04868773` - Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms